Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

clearpoint neuro inc - CLPT

CLPT

Close Chg Chg %
14.32 -1.43 -9.99%

Closed Market

12.89

-1.43 (9.99%)

Volume: 625.62K

Last Updated:

Jun 5, 2026, 4:00 PM EDT

Trade Now

Company Overview: clearpoint neuro inc - CLPT

CLPT Key Data

Open

$14.16

 Day Range

12.72 - 14.20

52 Week Range

8.27 - 30.10

 Market Cap

$429.45M

Shares Outstanding

29.99M

 Public Float

26.57M

Beta

1.31

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.01

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

681.46K

  

CLPT Performance

1 Week
 
 1.74%
 
1 Month
 
 0.55%
 
3 Months
 
 28.90%
 
1 Year
 
 -7.47%
 
5 Years
 
 -27.99%
 

CLPT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About clearpoint neuro inc - CLPT

ClearPoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

CLPT At a Glance

ClearPoint Neuro, Inc.
120 South Sierra Avenue
Solana Beach, California 92075
Phone 1-888-287-9109 Revenue 36.97M
Industry Medical Specialties Net Income -25,540,000.00
Sector Health Technology 2025 Sales Growth 17.78%
Fiscal Year-end 12 / 2026 Employees 172
View SEC Filings

CLPT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 10.477
Price to Book Ratio 14.338
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -18.227
Enterprise Value to Sales 10.81
Total Debt to Enterprise Value 0.146

CLPT Efficiency

Revenue/Employee 214,947.674
Income Per Employee -148,488.372
Receivables Turnover 5.09
Total Asset Turnover 0.528

CLPT Liquidity

Current Ratio 5.894
Quick Ratio 5.118
Cash Ratio 4.266

CLPT Profitability

Gross Margin 61.191
Operating Margin -65.359
Pretax Margin -68.932
Net Margin -69.081
Return on Assets -36.465
Return on Equity -95.639
Return on Total Capital -29.611
Return on Invested Capital -44.824

CLPT Capital Structure

Total Debt to Total Equity 207.823
Total Debt to Total Capital 67.514
Total Debt to Total Assets 57.719
Long-Term Debt to Equity 205.346
Long-Term Debt to Total Capital 66.709
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Clearpoint Neuro Inc - CLPT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
20.55M 23.95M 31.39M 36.97M
Sales Growth
+26.09% +16.56% +31.04% +17.78%
Cost of Goods Sold (COGS) incl D&A
7.02M 10.34M 12.27M 14.35M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
777.00K 1.46M 1.90M 2.24M
Depreciation
- 1.03M 1.12M 2.07M
Amortization of Intangibles
- 426.00K 780.00K 168.00K
COGS Growth
+40.18% +47.31% +18.63% +16.95%
Gross Income
13.53M 13.61M 19.12M 22.62M
Gross Income Growth
+19.84% +0.61% +40.46% +18.31%
Gross Profit Margin
+65.84% +56.83% +60.92% +61.19%
2022 2023 2024 2025 5-year trend
SG&A Expense
29.86M 36.06M 38.87M 46.79M
Research & Development
10.89M 11.71M 12.39M 13.90M
Other SG&A
18.97M 24.35M 26.48M 32.89M
SGA Growth
+21.07% +20.75% +7.79% +20.37%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(16.33M) (22.45M) (19.75M) (24.16M)
Non Operating Income/Expense
(22.00K) 357.00K 832.00K 1.07M
Non-Operating Interest Income
- 386.00K 872.00K 1.21M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 81.00K 2.39M
-
Interest Expense Growth
- - - -91.68%
-
Gross Interest Expense
- - 81.00K 2.39M
-
Interest Capitalized
- - - -
-
Pretax Income
(16.43M) (22.09M) (18.91M) (25.48M)
Pretax Income Growth
-14.05% -34.40% +14.37% -34.74%
Pretax Margin
-79.97% -92.21% -60.25% -68.93%
Income Tax
- - - 55.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(16.43M) (22.09M) (18.91M) (25.54M)
Minority Interest Expense
- - - -
-
Net Income
(16.43M) (22.09M) (18.91M) (25.54M)
Net Income Growth
-14.05% -34.40% +14.37% -35.03%
Net Margin Growth
-79.97% -92.21% -60.25% -69.08%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(16.43M) (22.09M) (18.91M) (25.54M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(16.43M) (22.09M) (18.91M) (25.54M)
EPS (Basic)
-0.6796 -0.8977 -0.6998 -0.902
EPS (Basic) Growth
+2.22% -32.09% +22.05% -28.89%
Basic Shares Outstanding
24.18M 24.61M 27.03M 28.32M
EPS (Diluted)
-0.6796 -0.8977 -0.6998 -0.902
EPS (Diluted) Growth
+2.22% -32.09% +22.05% -28.89%
Diluted Shares Outstanding
24.18M 24.61M 27.03M 28.32M
EBITDA
(15.55M) (20.99M) (17.84M) (21.93M)
EBITDA Growth
-22.65% -34.93% +14.99% -22.89%
EBITDA Margin
-75.69% -87.62% -56.84% -59.31%

Snapshot

Average Recommendation BUY Average Target Price 22.00
Number of Ratings 3 Current Quarters Estimate -0.287
FY Report Date 06 / 2026 Current Year's Estimate -1.113
Last Quarter’s Earnings -0.32 Median PE on CY Estimate N/A
Year Ago Earnings -0.90 Next Fiscal Year Estimate -0.94
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate -0.29 -0.26 -1.11 -0.94
High Estimates -0.25 -0.23 -1.01 -0.68
Low Estimate -0.33 -0.31 -1.24 -1.08
Coefficient of Variance -14.10 -15.81 -10.49 -23.98

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Clearpoint Neuro Inc - CLPT

Date Name Shares Transaction Value
Mar 17, 2026 Joseph Michael Burnett CEO and President; Director 139,061 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2026 Joseph Michael Burnett CEO and President; Director 95,900 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share 1,105,727.00
Mar 17, 2026 Joseph Michael Burnett CEO and President; Director 84,828 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2026 Danilo D’Alessandro Chief Financial Officer 119,285 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2026 Danilo D’Alessandro Chief Financial Officer 102,684 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share 1,183,946.52
Mar 17, 2026 Danilo D’Alessandro Chief Financial Officer 32,626 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2026 Jeremy L. Stigall Chief Business Officer 123,633 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2026 Jeremy L. Stigall Chief Business Officer 108,482 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share 1,250,797.46
Mar 17, 2026 Jeremy L. Stigall Chief Business Officer 30,995 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2026 Mazin Sabra Chief Operating Officer 80,624 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 17, 2026 Mazin Sabra Chief Operating Officer 67,343 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $11.53 per share 776,464.79
Mar 17, 2026 Mazin Sabra Chief Operating Officer 26,101 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Clearpoint Neuro Inc in the News